Physician profile
Caryn J Epperson
NPI 1467810739
$1,095.26
in general payments reported to CMS, 2019-2025
14 companies · $242 in 2025
The $242 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $73.91 · 2024: $779 · 2025: $242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,021.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,021.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $318.69 | 2024-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $139.18 | 2024-2025 | |
| Amgen INC. | $129.84 | 2024-2025 | Repatha, Repatha |
| Scpharmaceuticals INC. | $125.00 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $75.76 | 2024 | Arcalyst |
| Smith+Nephew, INC. | $73.91 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $52.35 | 2024 | Farxiga |
| Novo Nordisk INC | $44.97 | 2025 | Wegovy |
| Alnylam Pharmaceuticals INC. | $33.54 | 2024 | Amvuttra |
| E.R. Squibb & Sons, L.L.C. | $30.39 | 2024-2025 | Eliquis, Camzyos |
| Actelion Pharmaceuticals US, INC. | $27.66 | 2025 | Opsynvi, Uptravi |
| Merck Sharp & Dohme LLC | $19.63 | 2024 | Verquvo |
| Lexicon Pharmaceuticals, INC. | $15.42 | 2024 | |
| Vivaquant INC, Dba Rhythm Express | $8.92 | 2025 | Rhythm Express |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caryn Epperson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.